COMPARING SURVIVAL EXTRAPOLATION OUTCOMES USING DIFFERENT NETWORK META-ANALYSES (NMA) METHODS: AN APPLICATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED WITH IMMUNOTHERAPY (IO) BASED COMBINATIONS

被引：0
|
作者：
Krol, F. [1 ]
Depalma, S. [1 ]
El Alili, H. [1 ]
Verhoek, A. [1 ]
van Beekhuizen, S. [1 ]
Heeg, B. [1 ]
机构：
[1] Cytel Inc, Rotterdam, ZH, Netherlands
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MSR50
引用
收藏
页码：S359 / S359
页数：1
相关论文
共 50 条
  • [21] Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.
    Gan, Chun Loo
    Dudani, Shaan
    Wells, Connor
    Bakouny, Ziad
    Dizman, Nazli
    Pal, Sumanta K.
    Szabados, Bernadett
    Wood, Lori
    Kollmannsberger, Christian K.
    Agarwal, Neeraj
    Donskov, Frede
    Basappa, Naveen S.
    Bjarnason, Georg A.
    Parnis, Francis
    Porta, Camillo
    Davis, Ian D.
    Vaishampayan, Ulka N.
    Kanesvaran, Ravindran
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] IMMUNOTHERAPY-BASED COMBINATIONS IN THE FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH SARCOMATOID FEATURES: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Quhal, Fahad
    Mori, Keiichiro
    Laukhtina, Ekaterina
    Pradere, Benjamin
    Mostafaei, Hadi
    Rajwa, Pawel
    Shariat, Shahrokh F.
    Schmidinger, Manuela
    JOURNAL OF UROLOGY, 2022, 207 (05): : E174 - E174
  • [23] Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis
    Quhal, Fahad
    Mori, Keiichiro
    Fajkovic, Harun
    Remzi, Mesut
    Shariat, Shahrokh F.
    Schmidinger, Manuela
    CURRENT OPINION IN UROLOGY, 2022, 32 (01) : 61 - 68
  • [24] Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: A systematic review and network meta-analysis
    Quhal, F.
    Mori, K.
    Laukhtina, E.
    Rajwa, P.
    Mostafaei, H.
    Pradere, B.
    Shariat, S. F.
    Schmidinger, M.
    EUROPEAN UROLOGY, 2022, 81 : S591 - S592
  • [25] C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy
    Casamassima, A
    Picciariello, M
    Quaranta, M
    Berardino, R
    Ranieri, C
    Paradiso, A
    Lorusso, V
    Guida, M
    JOURNAL OF UROLOGY, 2005, 173 (01): : 52 - 55
  • [26] Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Gebrael, Georges
    Saad, Eddy
    Labaki, Chris
    Saliby, Renee Maria
    Sayegh, Nicolas
    Wells, J. Connor
    Semaan, Karl
    Eid, Marc
    Takemura, Kosuke
    Ernst, Matthew Scott
    Lemelin, Audreylie
    Basappa, Naveen S.
    Wood, Lori
    Powles, Thomas
    Ernst, D. Scott
    Kapoor, Anil
    Xie, Wanling
    Agarwal, Neeraj
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.
    Labaki, Chris
    Bakouny, Ziad
    Wells, J. Connor
    Takemura, Kosuke
    Saliby, Renee Maria
    Meza, Luis A.
    Gebrael, Georges
    Porta, Camillo
    Lee, Jae-Lyun
    Basappa, Naveen S.
    De Velasco, Guillermo
    Mckay, Rana R.
    Pal, Sumanta Monty
    Agarwal, Neeraj
    Donskov, Frede
    Braun, David A.
    Henske, Elizabeth
    Xie, Wanling
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [28] Incidence and severity of hypothyroidism and survival outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs).
    Bailey, Erin B.
    Tantravahi, Srinivas Kiran
    Wells, Chesley E.
    Straubhar, Alli M.
    Batten, Julia A.
    Poole, Austin
    Stenehjem, David D.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era
    Clark, Joseph I.
    Wong, Michael K.
    Daniels, Gregory A.
    Kaufman, Howard L.
    McDermott, David F.
    Morse, Michael A.
    Aung, Sandra
    BJU INTERNATIONAL, 2014, 114 : 5 - 5
  • [30] Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity
    Hermansen, Carina K.
    Donskov, Frede
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 827 - 833
12345